PET amyloid in patients at risk for Alzheimer's disease

European Regional Development Fund
OP Prague - the growth pole of the Czech Republic
Registrační číslo: CZ.07.1.02/0.0/16_023/0000116

Brief characteristics of the project: Early and accurate differential diagnosis of neurodegenerative dementias (most often Alzheimer's disease - ACH, then frontotemporal lobar degeneration, dementia with Lewy bodies, etc.) has been one of the most important topics in the field of cognitive neurology for several years. There is also some emphasis in the recent ACH diagnostic criteria on earlier diagnosis and a shift in the focus from clinical diagnosis to biomarker testing. The reasons may be exploratory, as current diagnostics, despite all efforts, are reaching limits and making it difficult to set up clean cohorts of patients, as well as clinical ones, as new early targeted treatment options are often in the final stages of development.

In vivo examination of beta-amyloid charge using PET is one of the new (available in the Czech Republic since 2015), but a very important and promising examination method, which allows both very accurate and early diagnosis of not only ACH


  1. Creation of software for evaluation of PET examination results for beta-amyloid, which will be usable for clinical and research purposes
  2. Creation of algorithms for technical processing of PET signal, fusion with MRI signal, implementation in clinical practice and research work.
  3. Define pure cohorts of amyloid-free controls in the brain and patients in a preclinical study or at risk of developing ACH for further longitudinal monitoring

Project realization: The project is implemented from 01.04. 2017 to 31.12. 2018 within the Cognitive Center of the Department of Neurology, 2nd Medical Faculty and Motol University Hospital.

Main researcher of the project: prof. MUDr. Jakub Hort, Ph.D.
Project manager: MUDr. Jiří Cerman

Skip to content